PubRank

J C Pechère

Author PubWeight™ 87.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997 5.91
2 Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol 2000 4.59
3 Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989 2.30
4 Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999 1.96
5 In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother 1986 1.71
6 Activity of ten antimicrobial agents against anaerobic bacteria. J Antimicrob Chemother 1978 1.66
7 Cellular events and intracellular survival of Campylobacter jejuni during infection of HEp-2 cells. Infect Immun 1989 1.65
8 Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 1992 1.62
9 Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987 1.62
10 In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother 1988 1.61
11 Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology 1990 1.61
12 A plasmid-mediated cephalosporinase from Achromobacter species. J Infect Dis 1982 1.55
13 Contribution of beta-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae. Antimicrob Agents Chemother 1987 1.55
14 Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994 1.51
15 Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microb Pathog 1990 1.42
16 Effect of motility and chemotaxis on the invasion of Salmonella typhimurium into HeLa cells. Microb Pathog 1990 1.38
17 Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003 1.33
18 Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res 1996 1.33
19 Identification of Campylobacter jejuni surface proteins that bind to Eucaryotic cells in vitro. Infect Immun 1990 1.32
20 Combination therapy: a way to limit emergence of resistance? Am J Med 1986 1.30
21 Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991 1.24
22 Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001 1.22
23 Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother 1991 1.16
24 Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother 1990 1.13
25 Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice. J Antimicrob Chemother 1988 1.12
26 In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother 1989 1.10
27 Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991 1.06
28 Effect of mucin on Campylobacter jejuni association and invasion on HEp-2 cells. Microb Pathog 1988 1.05
29 Development of beta-lactam-resistant Enterobacter cloacae in mice. J Infect Dis 1987 1.04
30 Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother 1994 1.02
31 In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother 1990 0.98
32 C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother 2001 0.97
33 Activity of minocycline against Toxoplasma gondii infection in mice. J Antimicrob Chemother 1991 0.96
34 Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci 1999 0.95
35 Fish oil decreases natural resistance of mice to infection with Salmonella typhimurium. Metabolism 1992 0.95
36 Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother 1989 0.95
37 Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother 1980 0.94
38 Genetic background of attenuated Salmonella typhimurium has profound influence on infection and cytokine patterns in human dendritic cells. J Leukoc Biol 2001 0.94
39 Respective role of polymorphonuclear leukocytes and their integrins (CD-11/18) in the local or systemic toxicity of lipopolysaccharide. J Leukoc Biol 1993 0.93
40 [Serum, lymph node and testicular concentrations of penicillin in 31 healthy or syphilitic rabbits treated with penicillin]. Pathol Biol (Paris) 1971 0.93
41 Arteether, a qinghaosu derivative, in toxoplasmosis. Trans R Soc Trop Med Hyg 1988 0.91
42 Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol 1983 0.91
43 Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients. Antimicrob Agents Chemother 1976 0.90
44 Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg 1991 0.90
45 Macrophage oxidative metabolism and intracellular Toxoplasma gondii. Microb Pathog 1989 0.90
46 Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother 1990 0.89
47 Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis 1991 0.89
48 Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother 1986 0.87
49 In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli. Infection 1994 0.87
50 Usual and unusual antibacterial effects of quinolones. J Antimicrob Chemother 1990 0.86
51 Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study. Drugs 1988 0.85
52 Laboratory survey of fluoroquinolone activity. Rev Infect Dis 1989 0.83
53 [Evolution of gentamicin sensitivity in acute postpartum staphylococcal endocarditis]. Ann Med Interne (Paris) 1972 0.83
54 Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection. J Antimicrob Chemother 1988 0.83
55 Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. J Antimicrob Chemother 1987 0.83
56 Overexpression, refolding, and purification of the histidine-tagged outer membrane efflux protein OprM of Pseudomonas aeruginosa. Protein Expr Purif 2001 0.82
57 Postantibiotic effect and host-bacteria interactions. J Antimicrob Chemother 1995 0.82
58 Treatment of vascular graft infection by in situ replacement with cryopreserved aortic allografts: an experimental study. J Vasc Surg 1998 0.81
59 Salmonella typhimurium thyA mutants fail to grow intracellularly in vitro and are attenuated in mice. Microbiology 2001 0.80
60 Anaerobic bacteria: evaluation of disc susceptibility to four cephalosporins. Infection 1978 0.80
61 In-vitro toxoplasmacidal activity of cationic electron carriers. J Antimicrob Chemother 1989 0.80
62 Open study of ceftazidime in serious infections due to multiply-resistant bacteria. J Antimicrob Chemother 1983 0.79
63 How predictable is development of resistance after beta-lactam therapy in Enterobacter cloacae infection? J Antimicrob Chemother 1989 0.79
64 Beta-lactamases: clinical and genetic perspectives. J Antimicrob Chemother 1983 0.79
65 Activity of roxithromycin against Toxoplasma gondii in murine models. J Antimicrob Chemother 1987 0.78
66 Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother 1994 0.78
67 Experimental treatment of vascular graft infection due to Staphylococcus epidermidis by in situ replacement with a rifampin-bonded polyester graft. Ann Vasc Surg 2001 0.78
68 Permeability and penicillin-binding protein alterations in Salmonella muenchen: stepwise resistance acquired during beta-lactam therapy. Antimicrob Agents Chemother 1989 0.78
69 Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. J Antimicrob Chemother 1992 0.78
70 [Encephalogram changes in common manifestations of herpetic primoinfection]. Ann Med Interne (Paris) 1969 0.77
71 Serum levels of ciprofloxacin after single oral doses in patients with septicemia. Eur J Clin Microbiol Infect Dis 1989 0.77
72 Dietary supplementation with fish oil enhances in vivo synthesis of tumor necrosis factor. Immunol Lett 1992 0.77
73 Activity of amphotericin B and intraconazole against intraphagocytic Candida albicans. Eur J Clin Microbiol Infect Dis 1990 0.76
74 Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology 1999 0.76
75 Rifampicin loading of vascular grafts. J Antimicrob Chemother 1996 0.75
76 Restrictive antibiotherapy after renal transplantation. Can Med Assoc J 1979 0.75
77 [Initial results of treament with rifampicin of some septicemic states, 4 of which with endocarditis]. Bull Mem Soc Med Hop Paris 1968 0.75
78 Relative beta-lactamase- and transpeptidase-inhibitory activities of the new quinolone WIN-57273 in Staphylococcus aureus. Antimicrob Agents Chemother 1992 0.75
79 Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents 1999 0.75
80 Does incubator noise increase risks of aminoglycoside ototoxicity? Audiology 1984 0.75
81 [Lincosamides]. Pathol Biol (Paris) 1986 0.75
82 Examination of enteropathogens for production of immunoglobulin A1 protease. Eur J Clin Microbiol 1985 0.75
83 Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria. J Antimicrob Chemother 1982 0.75
84 [Is it possible to recognize aminoglycoside ototoxicity early using evoked potentials?]. Ann Med Interne (Paris) 1980 0.75
85 [Active efflux. A disquieting bacterial resistance phenomenon]. Presse Med 1997 0.75
86 [Indications for respiratory resuscitation technics in whooping cough]. Therapeutique 1968 0.75
87 Prevention: toward a golden age. Infect Control Hosp Epidemiol 1998 0.75
88 [Determination of methoprime in organic liquids by a microbiological method]. Pathol Biol (Paris) 1970 0.75
89 "Chance makes a football of man's life". Infect Control Hosp Epidemiol 2000 0.75
90 New strategies against an old plague: genetically engineered tuberculosis vaccines. Schweiz Med Wochenschr 2000 0.75
91 [Synergism of trimethoprim-sulfamethoxazole association]. Pathol Biol (Paris) 1971 0.75
92 [Therapeutic results of bactericidal antibiotic associations in septicemia]. Pathol Biol (Paris) 1971 0.75
93 [New antibacterial vaccinal strategies]. Presse Med 1996 0.75
94 [Scarlatina]. Presse Med 1966 0.75
95 [Streptococcal septicemia (excluding Osler's endocarditis)]. Rev Prat 1977 0.75
96 [Scientific French in free-fall]. Union Med Can 1981 0.75
97 [Beta-lactams: present status and perspectives]. Presse Med 1984 0.75
98 [Abdominal suppurations: point of view of an infectious disease specialist]. Ann Chir 1985 0.75
99 [Current aspects of bacterial genetics: genotypic variations]. Gaz Med Fr 1965 0.75
100 [Developement of serum and urine concentrations of rifampicin during treatment]. Pathol Biol (Paris) 1969 0.75
101 [Compounds of the beta-lactam group as inhibitors of beta-lactamases]. Rev Prat 1982 0.75
102 [Experimental bacterial colonization of 3 types of arterial prosthesis]. Chirurgie 1983 0.75
103 Phagocytes, antibiotics and intracellular parasites: are the experimental data clinically relevant? Eur J Clin Microbiol Infect Dis 1991 0.75
104 [The role of cephalosporins in beta-lactam antibiotics. Mode of action. Concept of pharmacokinetics]. Rev Prat 1988 0.75
105 Experimental colonization of vascular grafts with Staphylococcus aureus. Can J Surg 1983 0.75
106 [Morbidity, mortality and etiology of gas gangrene in Canada]. Union Med Can 1981 0.75
107 Two-dimensional polyacrylamide gel electrophoresis isolation and microsequencing of Pseudomonas aeruginosa proteins. Enzyme Protein 1993 0.75